Af 150

Quick links to important sections

Af 150

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Af 150

Understanding Af 150

Af 150 is a pharmacological agent primarily classified as a muscarinic acetylcholine receptor antagonist, specifically targeting the M1 and M3 receptor subtypes. It is designed to modulate the parasympathetic nervous system's influence on various physiological processes.

Mechanism of Action

The active component in Af 150 works by binding to muscarinic receptors, which blocks the action of acetylcholine—a neurotransmitter responsible for transmitting signals that trigger involuntary muscle movements and glandular secretions. By inhibiting these specific receptors, the medication helps to reduce smooth muscle spasms and decrease the overactivity of certain bodily functions regulated by the cholinergic system.

Clinical Applications

This compound is typically utilized in the management of conditions characterized by hypermotility or excessive secretions. Its primary therapeutic roles include:

  • Gastrointestinal Regulation: Assisting in the reduction of gastric acid secretion and motility, which can be beneficial in treating certain digestive disturbances.
  • Ophthalmological Use: In clinical settings, it may be used to induce mydriasis (dilation of the pupil) and cycloplegia (paralysis of the ciliary muscle) for diagnostic examinations.
  • Secretory Control: Reducing excessive salivation or bronchial secretions in specific medical contexts.

Pharmacokinetics

Upon administration, Af 150 is absorbed into the systemic circulation and distributed throughout the body. It undergoes metabolic processing in the liver and is primarily excreted through the renal system. The duration of its effect is determined by its half-life and the affinity with which it binds to the target muscarinic receptors.

What side effects are possible with Af 150?

Possible Side Effects and Safety Information

Official regulatory documents classify the potential adverse reactions of Fluconazole, the active ingredient in Af 150, by their frequency and the body system affected. These classifications are based strictly on data observed in clinical trials and post-marketing surveillance.

Commonly Documented Adverse Reactions

Adverse reactions classified as Common (occurring in ge 1/100 to <1/10 patients) frequently involve the Gastrointestinal system (e.g., nausea, abdominal pain, diarrhea, vomiting) and the Nervous System (headache). Laboratory findings commonly include elevations in hepatic enzymes (ALT, AST, alkaline phosphatase).

Serious Adverse Reactions and Safety Constraints

The medicine's safety profile includes documentation of Rare but clinically significant adverse events across several System-Organ Classes. These serious reactions include fulminant hepatic failure and hepatocellular necrosis, which have been fatal, particularly in patients with serious underlying medical conditions. Severe cutaneous reactions, such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are also documented. Cardiovascular safety includes the risk of QT prolongation and the life-threatening arrhythmia Torsade de Pointes.

Population and Safety Notes

Specific safety considerations apply to certain populations. Patients with Impaired Hepatic or Renal Function require close monitoring as Fluconazole's clearance is affected. Fatal hepatic reactions and severe cutaneous events have been observed more frequently in individuals with serious underlying conditions such as AIDS or malignancy. The official label establishes Hypersensitivity to Fluconazole or related azoles as a formal contraindication, along with certain co-administered medications that increase the risk of serious cardiac events.

Overdose and Emergency Response

The official regulatory profile for an AF 150 (Fluconazole) overdose is defined by the potential for severe, high-concentration toxicity affecting the central nervous system (CNS) and the cardiovascular system.

Documented Overdose Manifestations

Overdose has been associated with specific neuro-psychiatric effects, including hallucination and paranoid behavior. The most severe, life-threatening outcomes are linked to cardiotoxicity, specifically the risk of significant QT interval prolongation and the development of Torsade de pointes—a serious ventricular arrhythmia.

Required Emergency Actions

It is mandated that immediate medical attention be sought upon suspected overdose exposure due to the documented severity of cardiac and CNS manifestations. Regulatory documents state that no specific antidote is available. Therefore, treatment is focused strictly on procedural and supportive management. Required actions include the institution of symptomatic treatment and general supportive measures, with gastric lavage potentially utilized if clinically appropriate. For reducing circulating drug levels, hemodialysis is a documented procedure capable of decreasing plasma concentrations by approximately 50 percent over a three-hour session. Due to the drug's primary reliance on renal excretion, patient kidney function is a critical consideration in the procedural management of clearance.

Therapeutic Uses of Af 150

Aflibercept (Af 150) is a specialized medication applied across domains where additional symptomatic support is needed for conditions linked to organ-specific functional stress in the eye. It may be part of symptomatic management for conditions characterized by periods of heightened symptoms. Its main uses are commonly applied during phases when symptoms become more noticeable.

This medication is relevant for easing symptoms that interfere with daily functioning and create noticeable physiological strain associated with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), and Retinopathy of Prematurity (ROP).

Quick Fact: Relief for Symptom Clusters that may become intense or disruptive

In clinical settings that involve acute or unstable symptom patterns, it assists with maintaining functional stability. The support offered helps maintain a sense of stability when symptoms are more noticeable, especially when groups of symptoms appear suddenly or fluctuate. The symptomatic assistance provided contributes to improved comfort during periods of heightened symptoms and helps patients cope more steadily with symptom fluctuations.

Eligibility and Restrictions for Use

Af 150 (Fluconazole) eligibility is determined by official regulatory criteria, focusing on absolute exclusions, specific health conditions, and age.

Contraindications and Restrictions

Classification Population or Condition
Contraindicated Patients with known hypersensitivity to fluconazole or other azole antifungals.
Use with QT-prolonging drugs metabolized by CYP3A4 (e.g., cisapride, pimozide, quinidine, erythromycin, and terfenadine at high doses) [See EMA/FDA].
Conditional Use Patients with Impaired Renal Function require dose adjustment for multiple-dose regimens.
Caution is advised for Hepatic Impairment or proarrhythmic Heart Conditions (e.g., advanced cardiac failure, electrolyte abnormalities).

Age and Physiological Eligibility

  • Adults and Adolescents (12–17 years) are generally eligible, though safety for the genital candidiasis indication is not established in pediatrics.
  • Infants under six months have limited data and require specific physician-determined dosing schedules due to slower drug elimination.
  • Pregnancy: Use is generally not recommended for short-term/standard doses. Chronic, high-dose use is classified by the FDA as Category D (Positive evidence of risk) due to reported congenital risks.
  • Lactation: May be maintained after a single low dose, but is not recommended after repeated or high-dose use.

What should I know about interactions with other medicines?

Af 150 Interactions with other medicines and products

Official regulatory documents describe a clinically significant interaction profile primarily rooted in Af 150's effect on certain Cytochrome P450 (CYP) enzymes in the liver, which are responsible for drug metabolism. The medicinal product is an established inhibitor of CYP2C9, CYP2C19, and CYP3A4 isozymes.

Interacting Agents and Constraints

  • Enzyme Substrate Medicines: Co-administration with medicines that are primarily metabolized by CYP2C9, CYP2C19, or CYP3A4 can significantly increase the concentration of the co-administered drug. Explicitly listed examples include the anticoagulant Warfarin, the anticonvulsants Phenytoin and Carbamazepine, and the sedative Midazolam. The concurrent use of these agents requires specific dose adjustments or intensive monitoring of the co-administered drug's concentration or effect (e.g., INR for Warfarin).
  • Enzyme Inducer Medicines: Co-administration with drugs that are potent inducers of CYP enzymes, such as Rifampicin (a strong CYP450 inducer), can decrease the plasma concentration of Af 150. This interaction may diminish the therapeutic effect of Af 150, and official documents mandate careful evaluation if this combination is unavoidable.
  • QT-Prolonging Agents: The product is associated with a risk of QT interval prolongation. Therefore, co-administration is not recommended with certain other medicines that are also known to prolong the QT interval (e.g., specific antiarrhythmics), due to the potential for an additive effect on the heart rhythm.

There are no specific constraints documented in the official regulatory sections regarding food or beverages that affect the product's systemic exposure.

Mechanism of Action

How Af 150 Works

Af 150 acts by engaging specific molecular targets to alter activity within key central nervous system signaling pathways. Its pharmacodynamic mechanism is characterized by a dual influence on monoamine and inhibitory systems, resulting in altered downstream signaling dynamics.

The compound is theorized to influence systems involving serotonin receptors and dopamine D2 receptors, exhibiting a dual receptor activity profile. This action is relevant in biological systems where targeted adjustments to core monoamine function are observed, influencing the intensity of downstream signaling.

Separately, Af 150 covers an effect on the GABAergic system, the brain's main inhibitory pathway. By modulating processes mediated by these inhibitory signaling patterns, the compound affects downstream transmission, which modifies the functional tone of targeted pathways. Furthermore, it engages mechanisms that influence feedback regulation within intracellular cascades, modifying early molecular steps that shape systemic signaling outcomes beyond initial receptor binding.

Dosage and Administration Information

How to Use Af 150

The administration of Af 150, whose active ingredient is Fluconazole, follows specific protocols detailed in prescribing information to ensure effective systemic use. The medicine is primarily administered through two approved routes: oral (using tablets, capsules, or suspension) and intravenous (IV) infusion. The oral form is highly absorbed, allowing patients to seamlessly switch from IV to oral administration using the same dose.

Dosing and Schedule Principles

For most multi-day treatments, the protocol mandates an initial Loading Dose on Day 1, which is double the amount of the subsequent Maintenance Dose. This is done to quickly achieve necessary therapeutic levels in the body. Maintenance therapy is typically administered once daily. For specific acute infections, a single oral dose of 150 mg is the standard. Certain long-term uses, such as suppressive therapy for recurrent infections, may follow a once-weekly frequency.

Administration and Adjustment Requirements

Fluconazole tablets and capsules may be taken with or without food, as absorption is not significantly impacted by meals. For the liquid oral suspension, the powder must be reconstituted with a specific amount of water as per instructions prior to use. A crucial procedural rule for chronic use involves dose adjustment based on kidney function. The protocol requires the daily maintenance dose to be reduced by 50% in adult patients with established renal impairment, as defined by a creatinine clearance of less than or equal to 50 mL/min. Pediatric dosing is determined using a milligram per kilogram (mg/kg) formula.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Af 150 (Fluconazole)

The research evidence for Af 150, which contains the active ingredient Fluconazole, comes from regulatory-reviewed studies that explore the evaluation of fungal infections. This overview focuses only on the research structure and the evidence context, not on advice or usage instructions.


Research Evidence for Systemic Fungal Infections

The body of evidence for serious, whole-body fungal infections, such as systemic candidiasis and cryptococcal meningitis, includes Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. These studies were designed to monitor outcomes related to systemic or functional imbalance.

Studies for Systemic Candidiasis

Research for systemic candidiasis was evaluated in short-term RCTs and observational studies. These studies primarily monitored measurements of survival and the rate of measurements of fungal clearance (clearance of the fungus from the blood or tissue). The findings describe patterns observed in studies related to fungal clearance when the medicine was evaluated in clinically stable adults. Outcomes may vary significantly depending on the specific Candida species.

Studies for Cryptococcal Meningitis

Research has explored three distinct phases of care: induction, consolidation, and maintenance. These studies mainly focused on adults with advanced HIV infection and monitored patterns in fungal clearance and relapse rates when the medicine was observed in the consolidation and maintenance phases.


Evidence for Prevention (Prophylaxis) in High-Risk Patients

Research has extensively explored the evaluation of the active ingredient to address fungal infections in people at very high risk, such as very low birth weight neonates and adults with neutropenia. The studies monitored outcomes linked to systemic imbalance, where data show patterns related to the overall incidence of invasive fungal infection and all-cause mortality during the defined risk period.


What Remains Uncertain in the Research Landscape

While a high volume of research describes the use of Fluconazole, certain key questions are still emerging. One significant area of ongoing research explores the patterns related to antifungal resistance. Research has observed in some studies that the widespread use of azoles was associated with the development of resistance in some fungal species. Long-term outcomes are not fully established, and comparative evidence is lacking for some of the less severe, superficial indications.

Key Studies & References IDSA Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer (Supports prophylaxis evidence)

Frequently Asked Questions (FAQ)

Common questions about Af 150 (FAQ)

Q: Is Af 150 a 'one and done' treatment, or is it typically a course of pills?

A: Af 150 (Fluconazole) can be used both ways, depending on the infection being treated. A single oral dose is the standard for certain acute infections, such as a vaginal yeast infection. However, for most other infections and for prevention, official documents indicate that it is prescribed as a course of pills administered over several days, weeks, or months.


Q: Why is it important to complete the full course of Af 150 even if symptoms improve?

A: Regulatory advice emphasizes the importance of adherence, as completing the full prescribed course is necessary to help ensure the infection is completely cleared. Stopping treatment early may be associated with the infection recurring or contributing to the development of antifungal resistance.


Q: Will taking Af 150 with food help reduce stomach upset?

A: Official product information states that Af 150 tablets can be taken with or without food because food does not significantly change how the medicine is absorbed. Since gastrointestinal upset (like nausea) is a common side effect, taking the dose with food is a common practice that may help ease stomach discomfort, although this is not officially recommended as part of the administration instructions.


Q: Does Af 150 interact with birth control pills?

A: Studies noted in regulatory documents show that Fluconazole may cause small to moderate increases in the blood levels of the hormone components (ethinyl estradiol and levonorgestrel) of some oral contraceptives. It is important for patients to ensure their healthcare team is aware of all medications they are taking, including birth control.


Q: What is the typical time frame to see full symptom resolution after taking Af 150?

A: The time it takes to see full symptom resolution varies greatly depending on the type and severity of the fungal infection. Some conditions require many weeks or months of treatment to achieve a cure. The completion of treatment is typically determined through professional monitoring of symptoms and laboratory tests.


Q: Can Af 150 cause long-term side effects if taken more than once?

A: While Af 150 is typically used short-term, rare cases of hair loss (alopecia) have been reported, primarily with higher doses taken for two months or longer. This effect is generally described as reversible after stopping the medication or significantly reducing the dose. Serious effects on the liver and heart are documented, and professional monitoring is typically part of prolonged treatment plans.


Q: What type of fungal infections affect the mouth and throat that Af 150 is used for?

A: Af 150 is indicated for the treatment of fungal infections affecting the mouth, commonly called oropharyngeal candidiasis (oral thrush), and the tube leading down to the stomach, known as esophageal candidiasis.


Q: Why is alcohol generally advised to be avoided while on Af 150?

A: Although regulatory documents do not list a specific chemical constraint, caution is advised because both alcohol and Af 150 are processed by the liver. Combining them may amplify common side effects such as headache, dizziness, and nausea. For individuals with pre-existing liver concerns, caution regarding alcohol is especially relevant, given the potential for additive effects.


Q: Can Af 150 be used for fungal infections that affect the nails?

A: Official prescribing information indicates that Fluconazole is approved for use in certain fungal infections of the nails, known as onychomycosis. This treatment option is usually considered when other methods are deemed unsuitable.


Q: Can Af 150 treat a bacterial infection in the vagina or urinary tract?

A: No, Af 150 is classified as an antifungal medication. It is effective only against infections caused by fungi or yeast. It is not designed to treat, or prevent, infections that are caused by bacteria or viruses.


Q: Can Af 150 be prescribed to children?

A: Yes, regulatory documents confirm that Fluconazole has approved uses for both children and infants. The dose is calculated specifically based on the child's weight and the specific type of fungal infection that needs treatment.


Q: How long does Af 150 stay in your system after a single dose?

A: According to the pharmacokinetics data in the official label, Af 150 has a half-life of about 30 hours in healthy adults. This means it takes approximately 30 hours for half of the drug to be eliminated from the body. Clearance from the system is typically achieved after multiple half-lives.


Q: Does Af 150 cause a change in how food tastes?

A: Yes, official reports of adverse reactions mention that a change in the way food tastes, sometimes called taste perversion or dysgeusia, is a reported side effect of Fluconazole.


Q: Can Af 150 make you drowsy or affect your ability to drive?

A: Regulatory safety information advises that central nervous system side effects such as dizziness or seizures may occasionally occur with this medication. Due to the possibility of these effects, caution is advised regarding activities requiring alertness, such as driving or operating machines.


Q: Can taking Af 150 be linked to hair loss in some users?

A: Yes, hair loss (alopecia) has been reported as a side effect, particularly in people taking high doses for a long period of time. This effect is generally described as being reversible once the medication is stopped or the dose is lowered.


Q: Is Af 150 used to prevent fungal infections in high-risk patients?

A: Yes, Af 150 is officially indicated for the prophylaxis (prevention) of candidiasis in certain high-risk patient populations. This includes patients undergoing procedures like bone marrow transplantation who are receiving intensive medical treatments.


Q: Can Af 150 cause skin rashes or peeling, and how serious is this?

A: Af 150 can cause a skin rash. Most are mild, but rare and severe skin reactions, including life-threatening conditions like Stevens-Johnson Syndrome (SJS), have been reported. If a severe rash appears, particularly during treatment for a deep infection, immediate consultation with a healthcare professional is necessary, as discontinuation of the drug may be warranted.


Q: Is Af 150 considered fungicidal (kills fungus) or fungistatic (stops growth)?

A: The official mechanism of action describes Af 150 as working by inhibiting a fungal enzyme necessary for cell membrane production. This action is responsible for its fungistatic activity, meaning it inhibits the growth and replication of the fungus.


Q: Does the efficacy of Af 150 decrease over time or with repeated use?

A: Regulatory documents acknowledge the potential for the development of resistance to fluconazole. Resistance involves genetic changes in the fungus that can reduce the effectiveness of the drug and potentially lead to treatment failure.


Q: What should I do if I forget to take my scheduled dose of Af 150?

A: If a dose is missed, it should be taken as soon as it is remembered, unless it is almost time for your next scheduled dose. In that case, the missed dose should be skipped, and the regular schedule should be resumed. Taking a double dose to make up for a missed one is generally not advised.


Q: What does the '150' mean in the name Af 150?

A: The '150' in the name typically refers to the common single-dose strength of the oral tablet or capsule, which contains 150 milligrams of the active ingredient Fluconazole.


Q: Why might a doctor prescribe a one-time high dose versus a lower, prolonged dose of Af 150?

A: The dosing strategy depends entirely on the type and severity of the fungal infection. A single dose is the standard approach for acute, localized infections, while a lower, prolonged dose is often used for more serious, systemic infections or for prevention (prophylaxis) in high-risk patients.


Q: Is it common to experience constipation or diarrhea with Af 150?

A: According to official reports of adverse reactions, diarrhea is commonly experienced in clinical studies. Constipation is also reported as a less common gastrointestinal side effect.


Q: What are the signs of liver injury that require stopping Af 150?

A: Official warnings state that signs of liver injury may include symptoms like right upper abdominal pain, loss of appetite, dark urine, or the yellowing of the skin or eyes (jaundice). If signs consistent with liver disease appear, a healthcare professional must be consulted, as the medication may need to be discontinued.


Q: Does Af 150 have a known interaction with any chemotherapy drugs?

A: Af 150 is often used to prevent infections in patients receiving chemotherapy. It can interact with drugs metabolized by certain liver enzymes (CYP enzymes). Because many chemotherapy agents fall into this category, close monitoring and potential dose adjustment is typically part of the management plan when these drugs are co-administered.

How should Af 150 be stored and disposed of?

Storage and Disposal of Fluconazole 150 mg

Official regulatory documents define strict conditions for the storage and disposal of fluconazole, primarily to maintain product stability and ensure environmental safety.

Scope Component Regulatory Requirement
Temperature Solid forms (capsules, tablets) must be stored at or below 30°C (86°F).
Container & Protection Keep the medicine in its original container with the cap tightly closed, away from excess heat and moisture.
Child Safety The medication must be kept out of the sight and reach of children.
Stability (Liquid) Reconstituted oral suspension must be stored between 5°C and 30°C and discarded after 14 days; freezing must be avoided.
Disposal Unused or expired medication should not be disposed of in household waste or wastewater. It must be returned to a pharmacist for proper disposal according to local environmental regulations, especially as the product waste is classified as potentially harmful to aquatic organisms.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Af 150 found in:

A-Z Index: